Evidence map›Paper›PMID 40230537›Full record

ArticleiScience2025

Combination therapy with alisertib enhances the anti-tumor immunity induced by a liver cancer vaccine.

Fang Xue, Jing Liu, Jinyan Wu, Xueer Li, Ningning Zhu, Shuting Tang, Mengli Zhang, Huan Duan, Rui Wang, Jing Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fang XueSchool of Nursing, Bengbu Medical University, Bengbu, Anhui 233030, China.
Jing LiuSurgical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China.
Jinyan WuSchool of Nursing, Bengbu Medical University, Bengbu, Anhui 233030, China.
Xueer LiSchool of Nursing, Bengbu Medical University, Bengbu, Anhui 233030, China.
Ningning ZhuSchool of Nursing, Bengbu Medical University, Bengbu, Anhui 233030, China.
Shuting TangSchool of Nursing, Bengbu Medical University, Bengbu, Anhui 233030, China.
Mengli ZhangSchool of Nursing, Bengbu Medical University, Bengbu, Anhui 233030, China.
Huan DuanIntensive Care Unit, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China.
Rui WangDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China.
Jing ZhangSchool of Mental Health, Bengbu Medical University, Bengbu, Anhui 233030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alisertib is a potent aurora A kinase inhibitor in clinical trials for cancer treatment, but its efficacy on cancer vaccines remains unclear. Here, we developed a DNA vaccine targeting glypican-3 (pGPC3) and evaluated its efficacy with alisertib in hepatocellular carcinoma (HCC) models. The combination therapy of pGPC3 vaccine and alisertib significantly inhibited subcutaneous tumor growth, enhanced the induction and maturation of CD11c

Indexed as

Biological sciencesCancer systems biologyImmunologyNatural sciencesSystems biology

Identifiers

PMID40230537
PMCPMC11995041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.